The mass spectrometry proteomics data have been deposited to the MassIVE data repository (Mass Spectrometry Interactive Virtual Environment) <ftp://MSV000083506@massive.ucsd.edu>. All other data is within the manuscript or can be obtained by inserting data from the manuscript into public databases identified within the manuscript.

Introduction {#sec005}
============

Multiple sclerosis is the most common chronic inflammatory demyelinating disease that affects mainly young adults \[[@pone.0230249.ref001]\]. The disease is progressive, and impacts the central nervous system with a complex pathomechanism involving both neurodegenerative and inflammatory characteristics \[[@pone.0230249.ref001]\]. The current disease modifying therapies aim to prevent relapses by suppressing inflammation in the relapsing--remitting form of the disease, but limited options are available to prevent demyelination or axonal degeneration \[[@pone.0230249.ref002]\]. Therefore, intensive research is going on to identify novel therapeutic targets.

The complexity and heterogeneity of multiple sclerosis pathology cannot be replicated by a single animal model; the most commonly used experimental autoimmune encephalomyelitis, and toxin- and/or virus-induced demyelination models capture only certain clinical and pathological features of the disease. The neurotoxin cuprizone (bis-cyclohexanoneoxalyldihydrazone, CPZ) causes reproducible, anatomically selective and reversible demyelination \[[@pone.0230249.ref003]\] that is not affected by the absence of T and B cells while the blood--brain barrier is considered to be intact \[[@pone.0230249.ref004]\]. Therefore, and in contrast to other multiple sclerosis models, de- and remyelination can be studied without interference from the contribution of adaptive immune responses \[[@pone.0230249.ref005]\].

Proteomic approach was successfully applied for studying pathomechanism \[[@pone.0230249.ref006], [@pone.0230249.ref007]\] of or finding new drug targets \[[@pone.0230249.ref008], [@pone.0230249.ref009]\] for various diseases. Interestingly, we found only three previous studies utilizing this approach for analysing CPZ-induced reversible demyelination \[[@pone.0230249.ref010]--[@pone.0230249.ref012]\]. None of them measured proteomic changes in the corpus callosum, where CPZ-induces the most pronounced demyelination \[[@pone.0230249.ref013]\]. Accordingly, in the present study, we assessed proteomic changes during de- and remyelination in the corpus callosum of CPZ treated mice.

Materials and methods {#sec006}
=====================

Materials {#sec007}
---------

Cuprizone (CPZ) was from Sigma-Aldrich (Budapest, Hungary) The Protease inhibitor mix without EDTA and PhosSTOP phosphatase inhibitor cocktail were from Roche Applied Science (Meylan, France). Benzonase was from Merck (Darmstadt, Germany). Lysyl endopeptidase (Lys-C) was from Wako Pure Chemical Industries (Osaka, Japan). Modified trypsin was from Promega (Madison, WI, USA). iTRAQ 4-plexTM was from Applied Biosystem (Foster City, CA, USA). Titanium dioxide beads were from GL Science (Japan). Poros Oligo R3 reversed phase chromatographic materials were from Applied Biosystems (Framingham, MA, USA). PHOS-select^TM^ metal chelate beads were from Sigma-Aldrich (St. Louis, MO, USA). TSK amide-80 HILIC 3 μm from Tosoh Bioscience (Stuttgart, Germany). 3M Empore C8 disk was from 3M Bioanalytical Technologies (St. Paul, MN, USA). All other reagents used in the experiments were of sequencing grade, and the water was from a Milli-Q system (Millipore, Bedford, MA).

Ethic statement and cuprizone treatment {#sec008}
---------------------------------------

The animal experiments were performed according to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health, and the protocol was approved by the Animal Research Review Committee, University of Pecs, Hungary. All animal experiments were controlled by trained personnel, and all efforts were made to minimize animal suffering.

C57BL/6 male mice were purchased from Charles River, Innovo Kft (Isaszeg, Hungary) and kept under standardized circumstances (controlled temperature, humidity and 12:12 h light-dark cycles.) Food and water were freely available.

Starting at 8 weeks of age, 20 animals were randomly assigned into 4 groups. Three groups were nourished with powdered rodent chow (1324 Altromin, Germany) containing 0.2% CPZ for 4 weeks ad libitum to induce demyelination, as described previously \[[@pone.0230249.ref014]\]. Control (C) group received the same without CPZ. To follow the methodical effect of CPZ treatment, the weights of the mice were measured twice a week \[[@pone.0230249.ref014]\], extent of demyelination was assessed by MRI imaging \[[@pone.0230249.ref015]\] at the end of CPZ treatment and before sacrificing the animals. The mice were sacrificed with cervical dislocation in deep isoflurane anaesthesia after termination of the treatment (4wD), and 2 (2dR) or 14 (2wR) days later. Brains were excised and the corpus callosums were dissected and snap-frozen on dry-ice. The samples were stored at −80°C until further processing.

Sample preparation {#sec009}
------------------

Dissected corpus callosums were homogenised in buffered solution (pH 7.5) consisting of protease and phosphatase inhibitors, 10mM DTT, 10mM sodium orthovanadate and benzonase (0.05%) using Dounce homogenizer, followed by probe sonication. Proteins were collected by centrifugation at 20000g after being precipitated by addition of 8 volumes of -20°C acetone and 1 volume of trichloroacetic acid. Protein pellets were solubilized with 6 M urea, 2 M thiourea, 10 mM DTT, followed by alkylating with iodoacetamide and digesting with lysyl endopeptidase and trypsin. Peptides were purified using homemade RP columns (both C8 and C18 resins were used) and labelled by isobaric tags (iTRAQ 4-plex^TM^**)** for relative quantitation. Based on amino acid composition analysis, equal amounts of samples were labelled as follow: Control, iTRAQ-114; 4 weeks demyelination, iTRAQ-115; 2 days remyelination, iTRAQ-116; and 2 weeks remyelination, iTRAQ-117 and combined in 1:1:1:1 ratio. In order to enrich for phosphopeptides and glycosylated peptides, the TiSH (TiO~2~-SIMAC-TiO~2~) protocol \[[@pone.0230249.ref016]\] was applied. Prior to the nano LC-MSMS identification, the phosporylated, deglycosylated and nonmodified peptides were fractionated by HILIC as described previously \[[@pone.0230249.ref017]\].

Liquid Chromatography--Mass Spectrometry (LC-MS) analysis {#sec010}
---------------------------------------------------------

The peptides were separated by reverse phase chromatography using homemade C18 column (3 μm, 75 μm x 150 mm) and gradient elution at a flow rate of 250 nl/min with an aid of Thermo EASY-nLC 1000 HPLC. Approximately 1 μg of peptide sample was loaded on the column. The buffer system consisted of solvent A (aqueous formic acid solution (0.1%) and solvent B (acetonitrile/formic acid (99.9/0.1%v/v). Gradient elution varied depending on the complexity of samples and was either 60 or 130 min from 0--34% solvent B, then 5--15 min for reaching 100% B and 10 min at 100% B. Eluted peptides were analysed by MS instruments (Orbitrap Velos and Q-Exactive, ThermoFisher). For the Velos instrument: scanning range was set to 400--1500 m/z for MS^1^ scans and the first mass fixed at 110 m/z for following 7 data dependent MS^2^ scans. Peptides were fragmented by HCD at 35 NCE. For the Q-Exactive instrument: scanning range was set to 350--1600 m/z for MS^1^ scans and the first mass fixed at 110 m/z for following 12 data dependent MS^2^ scans. Peptides were fragmented by HCD at 30 NCE. Raw datafiles were processed by Thermo Proteome Discoverer software v1.4. Protein identification was carried out by searching for *Mus musculus* taxonomically restricted in the databases of the NCBI and the Swiss-Prot using Mascot V2.4.1. Search parameters were set to allow two missed cleavage site, we accepted 15 ppm mass tolerance at MS^1^ and 0.02 Da at the MS^2^ mode and we searched for variable modifications including methionine oxidation, deamidation of Asn, phosphorylation on Ser/Thr/Tyr, peptide N-terminal iTRAQ labelling and lysine iTRAQ labelling and carbamidomethylation on cysteine as a fixed modification. The relevance threshold was set to \>20 MASCOT score. Data from ProteomeDiscoverer was further processed using Excel (Microsoft).

The mass spectrometry proteomics data have been deposited to the MassIVE data repository (Mass Spectrometry Interactive Virtual Environment) **<ftp://MSV000083506@massive.ucsd.edu>**

Immunohistochemistry {#sec011}
--------------------

We performed immunohistochemistry utilising protein phospho (p)-Ser, p-Thr and p-Tyr specific primary antibodies (Santa Cruz Biotechnology) on brain sections of the animals (n = 3) from all four treatment groups. Briefly, the chilled brains were removed, formalin-fixed, paraffin-embedded and sectioned (8 μm). The sections were dewaxed, exposed to 500 W microvawe for 3 x 5 min (antigene exposure) in 0.1 M citrate buffer pH 6.0, then the endogenous peroxidase activity was blocked in 0.1 M phosphate buffered saline (PBS) pH 7.4 containing 3% hydrogenperoxide for 20 min. The sections were blocked in PBS containing 0.2 10% bovine serum albumin (BSA) for 30 min, then were exposed to said primary and horseradish peroxidase conjugated anti-mouse IgG (Sigma) secondary antibodies in PBS containing 1% BSA overnight and for 1 h, respectively. Antibodies were diluted according to the manufacturer's recommendation, and between all steps a 3 x 5 min washing in PBS was performed. Antibodies were visualised by exposing the sections to 0.067% diaminobenzidine solution in PBS containing 0.02% hydrogen peroxide for 5--15 min against negative controls lacking primary and/or secondary antibody exposure. Nuclei were counterstained by Meyer's hematoxylin for 2 min then the sections were dehydrated and Balsam Canada (Sigma) mounted. The sections were scanned by Panoramic midi slide scanner at 1200 dpi resolution. For quantitative analysis, all nuclei and staining artefacts were eliminated from the sections and staining intensities of corpus callosums were normalised to that of left and right retrosplenial area, ventral part, layer 1 by an expert blind to the experiment by using Molecular Devices' MetaXpress® image analyser software.

Gene Ontology (GO), pathway and functional correlation analyses {#sec012}
---------------------------------------------------------------

Deregulated proteins were categorised into protein classes using Protein Analysis Through Evolutionary Relationships (PANTHER) classification system software ([http://www.pantherdb.org](http://www.pantherdb.org/)) and the general annotation from UniProt ([http://uniprot.org](http://uniprot.org/)). For clustering, we used the Perseus software platform ([http://www.perseus-framework.org](http://www.perseus-framework.org/)) developed by the Max Planck Institute of Biochemistry (<https://maxquant.net/perseus/>). Gene ontology (GO) analysis of biological processes and cellular components was performed with PANTHER software. Regulatory network prediction was performed by Ingenuity Pathway Analysis (IPA) software (Qiagen Inc. <https://digitalinsights.qiagen.com/products-overview/discovery-insights-portfolio/analysis-and-visualization/qiagen-ipa/>) utilising Ingenuity Knowledge Base, a highly structured repository of biological interactions and functional annotations.

Statistical analyses {#sec013}
--------------------

The protein and phosphopeptide intensities within each condition were normalised to the total peptide amount. The fold changes of the different conditions were estimated using the average control abundances from five biological replicates. The log2 transformed protein ratios and differential expression were analysed using limma and stats packages \[[@pone.0230249.ref018]\]. Phosphopeptide abundances were further normalized against the abundance of the non-modified proteins. The ratios of proteins were regarded as being significantly changed between conditions compared if the q value was less than 0.05.

For comparing multiple groups, one-way ANOVA was performed followed by Tukey's post-hoc test. Groups were considered to be significantly different when p value was less than 0.05.

Differential expression of IPA predicted regulatory genes among human multiple sclerosis lesion types vs. nonaffected white matter (NAWM) was identified by using the edgeR package (3.8) software \[[@pone.0230249.ref019]\] from the database created previously \[[@pone.0230249.ref020]\]. Adjusted p value filtering using the procedure of Benjamini and Hochberg was used to establish significant differences.

Results {#sec014}
=======

De- and remyelination affected about 5.5% of the proteins identified {#sec015}
--------------------------------------------------------------------

In an attempt to identify key elements regulating de- and remyelination, we isolated and homogenized the corpus callosum from mice exposed to CPZ, and performed liquid-chromatography mass-specrometry analysis from the homogenates. Following the same protocol we have used for studying transcriptome changes and the effect of microRNA-146a on CPZ-induced demyelination \[[@pone.0230249.ref014], [@pone.0230249.ref021]\], we induced demyelination in all mice except the controls (C) for 4 weeks with 0.2% CPZ (4wD), then allowed remyelination by terminating CPZ supplementation for 2 days (2dR) and 2 weeks (2wR). From the 20 samples (5 mice per group) we could identify altogether 3183 unmodified proteins. In addition to the unmodified ones, we detected 6017 single- or multi phosphorylated and/or gycosylated (PTM) peptides. Based on them, we identified 1703 PTM proteins. We performed clustering of these proteins for visualization how their level changed during de- and remyelination. Initially, pattern of protein level changes became markedly more coherent as the number of clusters was increased. However, the coherency did not increase significantly by increasing the number of clusters from 7 to 8. Therefore, we selected 7 clusters for both the unmodified ([Fig 1A](#pone.0230249.g001){ref-type="fig"}) and PTM proteins ([Fig 1B](#pone.0230249.g001){ref-type="fig"}). However, the proportional distribution ([Fig 1A and 1C](#pone.0230249.g001){ref-type="fig"}) of the proteins among the clusters differed. So did the directions of the protein level changes ([Fig 1C and 1D](#pone.0230249.g001){ref-type="fig"}) among the different experimental groups within the given clusters. Furthermore, while for the unmodified proteins, demyelination was found to be more closely related to late remyelination ([Fig 1A](#pone.0230249.g001){ref-type="fig"}) by the Perseus algorithm, it was early remyelination for the PTM proteins ([Fig 1B](#pone.0230249.g001){ref-type="fig"}). All these data indicated that clustering the whole protein population, although provided a basic visualisation of the changes the proteins followed during de- and remyelination, did not provide any clear lead toward finding proteins that conceivably regulate de- or remyelination.

![Cluster analysis.\
Mice were treated or not (C) with 0.2% cuprizone in their food for 4 weeks then were sacrificed after termination of the treatment (4wD), and 2 (2dR) or 14 (2wR) days later. Cluster analysis of 3183 unmodified **(A** and **C)** and 1703 single- or multi phosphorylated and/or gycosylated proteins **(B** and **D)** identified in corpus callosum homogenate of the mice were performed by using the Perseus software platform ([http://www.perseus-framework.org](http://www.perseus-framework.org/)). Heat maps **(A** and **B)** and pattern of protein concentration changes in the treatment groups **(C** and **D)** are presented. The concentrations were normalised to those of C group and were expressed in log~2~(fold change) values. Heat map scales are z score based, number of the proteins in a given cluster **(A** and **B)** as well as cluster ID next to a given cluster pattern **(C** and **D)** are indicated.](pone.0230249.g001){#pone.0230249.g001}

For further analysis, we used those 1970 unmodified and 1255 PTM proteins only that were present in at least 80% of the samples. Furthermore, we considered the protein level to be significantly altered when (i) the protein's identification was based on at least two unique peptides, (ii) it differed from the control significantly (q\<0.05) and (iii) level of the unique peptides changed parallel to each-other. We identified 161 such unmodified proteins ([Table 1](#pone.0230249.t001){ref-type="table"}); 93 of increased and 68 of decreased level during de- and remyelination, respectively ([Fig 2A](#pone.0230249.g002){ref-type="fig"}). Out of the 1255 single- or multi phosphorylated and/or gycosylated proteins, 40 were significantly affected by de- and remyelination ([Table 2](#pone.0230249.t002){ref-type="table"} and [Fig 2B](#pone.0230249.g002){ref-type="fig"}). Interestingly, these protein populations did not overlap; we could not find any protein that significantly changed one way by the CPZ treatment and the other way when CPZ treatment was discontinued. We found only nine proteins that were identified both as PTM and unmodified ones (Tables [1](#pone.0230249.t001){ref-type="table"} and [2](#pone.0230249.t002){ref-type="table"}; grey shading). Among the PTM proteins of elevated level, 30% were phosphorylated ([Table 2](#pone.0230249.t002){ref-type="table"}; yellow shading), the rest were N-glycosylated. In contrast, 92% of the PTM proteins of decreased level were at least monophosphorylated ([Table 2](#pone.0230249.t002){ref-type="table"}; yellow shading).

![Venn diagrams for the proteins significantly altered in the experimental groups.\
Distribution of unmodified **(A)** and single- or multi phosphorylated and/or gycosylated proteins **(B)** among the different experimental groups are presented. Numbers indicate the number of the proteins in Tables [1](#pone.0230249.t001){ref-type="table"} and [2](#pone.0230249.t002){ref-type="table"}.](pone.0230249.g002){#pone.0230249.g002}
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###### Concentrations of unmodified proteins significantly affected by de- and remyelination.

![](pone.0230249.t001){#pone.0230249.t001g}

  access \#   Protein                                           4wD      q       2dR      Q       2wR      q
  ----------- ------------------------------------------------- -------- ------- -------- ------- -------- -------
  O35639      Annexin A3                                        1.129    0.000   0.877    0.004   0.613    0.027
  O89017      Legumain                                          1.591    0.000   1.025    0.002   0.708    0.009
  P03995      Glial fibrillary acidic protein                   1.465    0.000   1.333    0.000   1.733    0.000
  P07356      Annexin A2                                        0.947    0.001   0.741    0.016   0.567    0.017
  P14106      Complement C1q subcomponent subunit B             1.126    0.000   0.792    0.007   1.578    0.000
  P16110      Galectin-3                                        2.181    0.002   1.616    0.002   1.632    0.003
  P18242      Cathepsin D                                       1.262    0.000   0.753    0.003   0.729    0.000
  P20152      Vimentin                                          1.562    0.000   1.107    0.000   1.275    0.000
  P24452      Macrophage-capping protein                        1.196    0.000   0.815    0.017   1.457    0.000
  P26041      Moesin                                            0.885    0.007   0.841    0.000   0.627    0.000
  P31786      Acyl-CoA-binding protein                          0.700    0.026   0.792    0.006   0.505    0.001
  Q61233      Plastin-2                                         1.009    0.007   0.735    0.011   0.789    0.000
  Q8BTM8      Filamin-A                                         0.701    0.002   0.434    0.031   0.276    0.049
  Q99L04      Dehydrogenase/reductase SDR family 1              1.024    0.001   0.698    0.011   0.712    0.000
  Q9DAW9      Calponin-3                                        0.949    0.002   0.570    0.027   0.752    0.000
  Q9WUU7      Cathepsin Z                                       1.538    0.001   0.926    0.006   1.181    0.004
  P20060      Beta-hexosaminidase subunit beta                  1.168    0.000   0.503            0.895    0.000
  P29758      Ornithine aminotransferase, mitochondrial         0.404    0.032   0.385            0.304    0.040
  Q9JLF6      Gamma-glutamyltransferase K                       1.605    0.006   1.204            1.714    0.004
  O08709      Peroxiredoxin-6                                   0.598    0.014   0.448            0.759    0.000
  P10605      Cathepsin B                                       0.749    0.003   0.137            0.511    0.004
  P16045      Galectin-1                                        1.062    0.002   0.508            0.749    0.002
  P68033      Actin, alpha cardiac muscle 1                     1.886    0.002   0.986            1.404    0.004
  P84075      Neuron-specific calcium-binding protein           0.775    0.012   0.390            0.806    0.000
  P97371      Proteasome activator complex subunit 1            0.630    0.019   0.337            0.480    0.003
  Q02105      Complement C1q subcomponent subunit C             1.102    0.001   0.504            1.725    0.000
  Q61599      Rho GDP-dissociation inhibitor 2                  0.805    0.001   0.420            0.387    0.026
  Q8BMS1      Trifunctional enzyme subunit alpha                0.437    0.030   0.307            0.318    0.026
  P48036      Annexin A5                                        0.349            0.464    0.030   0.396    0.004
  P61205      ADP-ribosylation factor 3                         1.228            0.920    0.043   0.779    0.004
  P58771      Tropomyosin alpha-1 chain                         0.231            0.671    0.039   1.172    0.004
  P47955      60S acidic ribosomal protein P1                   0.541            0.414            0.315    0.027
  P56564      Excitatory amino acid transporter 1               0.390            0.232            0.451    0.012
  P98086      Complement C1q subcomponent subunit A             0.820            0.596            1.510    0.000
  Q9EQU5      Protein SET                                       0.423            0.160            0.477    0.004
  Q06890      Clusterin                                         0.039            0.346            0.779    0.000
  O35658      Complement component 1 Q-binding protein          0.431            0.265            0.536    0.047
  P03921      NADH-ubiquinone oxidoreductase chain 5            0.469            0.528            0.393    0.029
  P08226      Apolipoprotein E                                  0.518            0.397            0.846    0.000
  P28798      Granulins                                         0.926            0.080            1.449    0.004
  P29416      Beta-hexosaminidase subunit alpha                 0.578            0.496            0.516    0.026
  P42225      Signal transducer/transcription activator 1       0.482            0.512            0.732    0.034
  P51880      Fatty acid-binding protein, brain                 0.810            0.291            0.880    0.000
  P55264      Adenosine kinase                                  0.013            -0.182           0.321    0.038
  P56565      Protein S100-A1                                   0.582            0.614            0.664    0.001
  P62082      40S ribosomal protein S7                          0.335            0.190            0.271    0.048
  P63040      Complexin-1                                       0.482            -0.019           0.656    0.003
  P70202      Latexin                                           0.359            0.233            0.446    0.003
  P97372      Proteasome activator complex subunit 2            0.634            -0.456           0.905    0.014
  P99027      60S acidic ribosomal protein P2                   0.357            0.244            0.544    0.006
  Q61207      Sulfated glycoprotein 1                           0.444            0.299            0.612    0.006
  Q8BGC4      Zinc-binding ADH domain-containing protein 2      0.243            -0.274           0.479    0.032
  Q9Z127      Large neutral amino acids transporter 1           0.519            0.310            0.689    0.004
  Q9Z1T2      Thrombospondin-4                                  -0.661           0.211            1.371    0.016
  P17225      Polypyrimidine tract-binding protein 1            0.681    0.009   0.473    0.021   0.221    
  Q62417      Sorbin and SH3 domain-containing protein 1        0.530    0.016   0.447    0.034   0.212    
  Q9JM63      ATP-sensitive inward rectifier K^+^ channel 10    0.730    0.024   0.940    0.004   0.222    
  P62849      40S ribosomal protein S24                         0.830    0.007   0.246            0.593    
  Q00915      Retinol-binding protein 1                         0.622    0.009   0.166            0.431    
  Q8R0Y6      10-formyltetrahydrofolate dehydrogenase           0.331    0.038   0.164            0.270    
  Q9D379      Epoxide hydrolase 1                               0.904    0.002   0.396            0.430    
  Q9DCN2      NADH-cytochrome b5 reductase 3                    0.714    0.001   0.368            0.343    
  Q9JJU8      SH3-binding glutamic acid-rich-like protein       0.480    0.036   0.311            0.280    
  Q9WV32      Arp 2/3 complex subunit 1B                        0.691    0.046   0.344            0.409    
  O08677      Kininogen-1                                       0.818    0.042   0.302            -0.039   
  O88958      Glucosamine-6-phosphate isomerase 1               0.614    0.040   0.314            0.374    
  P11352      Glutathione peroxidase 1                          0.500    0.019   0.260            -0.022   
  P17047      Lysosome-associated glycoprotein 2                0.612    0.006   0.346            0.218    
  P26039      Talin-1                                           0.646    0.012   0.396            0.244    
  Q05816      Fatty acid-binding protein, epidermal             0.939    0.007   0.053            0.468    
  Q3UHB1      5\'-nucleotidase domain-containing protein 3      0.504    0.036   0.339            0.167    
  Q62348      Translin                                          0.524    0.046   0.333            0.103    
  Q8VDD5      Myosin-9                                          0.535    0.035   0.301            0.230    
  Q9D0S9      Histidine triad nucleotide-binding protein 2      0.403    0.046   0.251            0.082    
  Q9Z110      Delta-1-pyrroline-5-carboxylate synthase          0.550    0.020   0.313            0.013    
  Q9Z1E4      Glycogen \[starch\] synthase                      0.966    0.046   -0.055           0.331    
  O54983      Ketimine reductase mu-crystallin                  0.578            0.489    0.026   0.193    
  Q08331      Calretinin                                        0.695            1.042    0.038   0.179    
  Q9DB73      NADH-cytochrome b5 reductase 1                    0.326            0.404    0.039   0.130    
  Q9Z0F7      Gamma-synuclein                                   0.709            0.696    0.014   -0.224   
  P03888      NADH-ubiquinone oxidoreductase chain 1            0.977            0.839    0.039   0.583    
  P07309      Transthyretin                                     0.249            0.743    0.004   -0.047   
  P07724      Serum albumin                                     0.364            0.572    0.019   0.167    
  P10126      Elongation factor 1-alpha 1                       0.102            0.555    0.011   -0.072   
  P23492      Purine nucleoside phosphorylase                   0.248            0.539    0.011   0.055    
  P34884      Macrophage migration inhibitory factor            0.882            0.502    0.026   0.158    
  P63038      60 kDa heat shock protein, mitochondrial          0.233            0.412    0.039   0.152    
  Q6PE15      Mycophenolic acid acyl-glucuronide esterase       0.520            0.477    0.039   0.202    
  Q9CQI6      Coactosin-like protein                            0.129            0.554    0.039   0.228    
  Q9D1I5      Methylmalonyl-CoA epimerase                       0.121            0.695    0.039   0.050    
  Q9DBS2      Tumor p63-regulated gene 1-like protein           0.548            0.544    0.030   0.172    
  Q9QYG0      Protein NDRG2                                     0.731            0.595    0.038   0.380    
  Q9R0P9      Ubiquitin hydrolase L1                            0.399            0.624    0.011   0.151    
  P97315      Cysteine and glycine-rich protein 1               -0.704   0.007   -0.667   0.004   -0.390   0.014
  Q5EBJ4      Ermin                                             -1.053   0.000   -0.818   0.033   -0.641   0.020
  Q8K298      Actin-binding protein anillin                     -0.681   0.008   -0.912   0.011   -0.902   0.000
  Q8R3P0      Aspartoacylase                                    -0.617   0.016   -0.883   0.000   -0.839   0.000
  Q8BR63      Protein FAM177A1                                  -0.646   0.037   -0.698           -0.846   0.002
  P16330      2\',3\'-cyclic-nucleotide 3\'-phosphodiesterase   -0.492   0.042   -0.537           -0.593   0.004
  P23927      Alpha-crystallin B chain                          -0.836   0.011   -0.446           -0.727   0.029
  Q05BC3      Echinoderm microtubule-associated 1               -0.707   0.016   -0.467           -0.422   0.012
  Q9CRB6      Tubulin polymerization-promoting protein 3        -0.658   0.007   -0.388           -0.702   0.000
  Q9D8B7      Junctional adhesion molecule C                    -1.109   0.003   -0.577           -0.665   0.027
  Q7M750      Opalin                                            -0.577           -0.803   0.007   -0.937   0.000
  Q9D154      Leukocyte elastase inhibitor A                    -0.442           -0.606   0.006   -0.596   0.003
  Q5SYD0      Unconventional myosin-Id                          -0.251           -0.505   0.016   -0.566   0.006
  O54988      STE20-like serine/threonine-protein kinase        -0.290           -0.238           -0.271   0.032
  Q8CAY6      Acetyl-CoA acetyltransferase, cytosolic           -0.771           0.074            -0.407   0.007
  O70172      PI 5-phosphate 4-kinase type-2 alpha              -0.183           -0.352           -0.401   0.008
  Q921C1      Gap junction gamma-3 protein                      -2.460           0.200            -1.248   0.033
  Q62433      Protein NDRG1                                     -0.305           -0.404           -0.490   0.005
  P08553      Neurofilament medium polypeptide                  -0.232           -0.158           -0.387   0.029
  P84096      Rho-related GTP-binding protein RhoG              -0.434           -0.454           -0.635   0.001
  P40237      CD82 antigen                                      -0.509           -0.475           -0.707   0.033
  P40240      CD9 antigen                                       -0.232           -0.353           -0.732   0.000
  P00920      Carbonic anhydrase 2                              -0.469           -0.417           -0.599   0.006
  P61329      Fibroblast growth factor 12                       -0.662           0.073            -0.599   0.000
  P62746      Rho-related GTP-binding protein RhoB              -0.422           -0.190           -0.337   0.014
  P97370      Na^+^/K^+^-transporting ATPase beta-3             -0.430           -0.383           -0.289   0.037
  Q3TUF7      YEATS domain-containing protein 2                 -0.408           -0.622           -0.934   0.037
  Q64012      RNA-binding protein Raly                          -0.353           0.021            -0.883   0.004
  Q8BGN3      Ectonucleotide phosphodiesterase 6                -0.296           -0.328           -0.588   0.006
  Q8BVI4      Dihydropteridine reductase                        -0.197           -0.163           -0.315   0.027
  Q8CIG8      Protein arginine N-methyltransferase 5            -0.079           0.078            -0.321   0.043
  Q8R366      Immunoglobulin superfamily member 8               -0.132           -0.163           -0.345   0.023
  Q64487      Receptor-type tyrosine-phosphatase delta          -0.380           -0.094           -0.295   0.034
  Q8VDQ8      Sirtuin-2                                         -0.154           -0.097           -0.501   0.006
  Q99J77      Sialic acid synthase GN = Nans                    -0.644           0.072            -0.366   0.032
  Q9EQF6      Dihydropyrimidinase-related protein 5             -0.072           -0.001           -0.621   0.006
  Q9R1V7      Disintegrin and MPD-containing protein 23         -0.219           -0.078           -0.313   0.044
  Q8BH66      Atlastin-1                                        -0.349           -0.107           -0.259   0.038
  Q920E5      Farnesyl pyrophosphate synthase                   -0.502   0.019   -0.452   0.039   -0.244   
  Q9WV27      Na^+^/K^+^-transporting ATPase alpha-4            -0.703   0.036   -0.916   0.011   -0.415   
  Q9Z2Y3      Homer protein homolog 1                           -0.462   0.046   -0.366   0.039   -0.090   
  P00158      Cytochrome b                                      -1.776   0.003   -0.544           -0.483   
  P62071      Ras-related protein R-Ras2                        -0.868   0.028   -0.314           -0.422   
  Q8C078      Calcium/calmodulin-dependent PKK 2                -0.851   0.002   -0.223           -0.337   
  P07759      Serine protease inhibitor A3K                     -0.636   0.042   -0.504           -0.052   
  P11881      Inositol 1,4,5-trisphosphate receptor type 1      -0.396   0.046   -0.153           -0.084   
  P12023      Amyloid beta A4 protein                           -0.593   0.005   -0.315           -0.179   
  P15105      Glutamine synthetase                              -0.574   0.006   -0.240           -0.162   
  P28661      Septin-4                                          -0.353   0.046   -0.493           -0.305   
  Q14BB9      MAP6 domain-containing protein 1                  -0.586   0.036   -0.357           -0.167   
  Q5SVL6      Rap1 GTPase-activating protein 2                  -0.498   0.019   0.040            -0.186   
  Q8CHH9      Septin-8                                          -0.348   0.046   -0.387           -0.221   
  Q61699      Heat shock protein 105 kDa                        -0.321   0.032   -0.137           -0.080   
  Q6PDY2      2-aminoethanethiol dioxygenase                    -0.505   0.041   -0.387           -0.182   
  Q80YN3      Breast carcinoma-amplified seq1 homolog           -0.860   0.000   -0.685           -0.552   
  Q99PJ0      Neurotrimin                                       -0.453   0.020   -0.351           -0.145   
  Q9EPL2      Calsyntenin-1                                     -0.564   0.011   -0.598           -0.083   
  Q9QUR8      Semaphorin-7A                                     -0.425   0.032   -0.287           -0.206   
  Q9WV34      MAGUK p55 subfamily member 2                      -0.330   0.047   -0.339           -0.092   
  P13020      Gelsolin                                          -0.425   0.028   -0.386           -0.005   
  Q8CC35      Synaptopodin                                      -0.415   0.042   -0.488           -0.055   
  Q3UTJ2      Sorbin and SH3 domain-containing protein 2        -0.271           -0.422   0.034   -0.069   
  Q922U2      Keratin, type II cytoskeletal 5                   -1.424           -1.565   0.050   -0.674   
  P02535      Keratin, type I cytoskeletal 10                   -0.873           -1.023   0.033   -0.561   
  P35803      Neuronal membrane glycoprotein M6-b               -0.246           -0.413   0.043   -0.025   
  Q8K2K6      Arf-GAP domain and FG repeat-containing 1         -0.295           -0.438   0.039   -0.040   
  Q8K406      Leucine-rich repeat LGI family member 3           -0.207           -0.424   0.038   -0.255   
  O35405      Phospholipase D3                                  -0.492           -0.637   0.002   -0.151   

The concentrations of the proteins in the different experimental groups were normalised to those of C group and were expressed in log~2~(fold change) values. Significant difference from the control is indicated by presenting the q value, and shading red the increases and green the decreases. Those proteins that were identified as both unmodified and single- or multi phosphorylated and/or gycosylated are shaded grey.

10.1371/journal.pone.0230249.t002

###### Concentrations of single- or multi phosphorylated and/or gycosylated (PTM) proteins significantly affected by de- and remyelination.

![](pone.0230249.t002){#pone.0230249.t002g}

  Peptide sequence                  access \#   protein              4wD      q       2dR      q       2wR      q
  --------------------------------- ----------- -------------------- -------- ------- -------- ------- -------- -------
  AVLVNdNITTGEK                     Q91XA2      Golgi membr. p1      1.961    0.001   1.339    0.011   1.225    0.030
  VFIVPVGdNHSNIPFSR                 Q8BG07      Phospholipase D4     1.319    0.047   1.679    0.003   1.861    0.008
  APIPTALDTdNSSK                    Q07797      Galectin-3-binding   1.994    0.001   2.113    0.000   1.993    0.001
  ALGYEdNATQALGR                                                     2.109    0.001   1.984    0.000   2.046    0.003
  GLdNLTEDTYKPR                                                      2.690    0.001   2.524    0.004   2.724    0.000
  dNLTTLGIFGAATNK                   Q80WV3      Carbohydrate ST2     1.601    0.003   0.729            1.305    0.035
  LdNFTGPGEPDSLR                    P11835      Integrin beta-2      1.384    0.011   0.954            1.606    0.006
  VLTNQESPYQdNHTGR                  P98086      Complement C1q       1.751            1.789    0.010   2.306    0.001
  ATVdNDSGEYR                       P08508      IG-G Fc receptor3    2.005            0.816            1.818    0.016
  LLdNLTSPEATAK                     O55026      EcTP DPase2          0.847            0.404            1.029    0.030
  TGEPDEEEGTFRpSSIR                 Q9Z239      Phospholemman        0.653            0.607            1.408    0.004
  SPPDQSAVPNpTPPSTPVKLEEDLPQEPTSR   Q9QYC0      Alpha-adducin        0.387            -0.489           1.455    0.030
  QELdNDSLQVAER                     Q06890      Clusterin            -0.284           0.052            1.655    0.014
  dNSTGCLK                                                           0.558            0.895            1.896    0.014
  ETISAIDpTSPK                      Q3UH99      Protein shisa-6      1.839    0.015   1.513    0.014   1.288    
  VLGFKPKPPKdNESLETYPLMMK           P14094      NA^+^/K^+^ ATPase    2.710    0.007   2.268    0.007   1.588    
  dNSTFGSVEVFSLDPNK                 P56528      cADP hydrolase 1     1.695    0.040   1.569            0.711    
  YYHGELSYLdNVTRK                   P18242      Cathepsin D          1.540    0.046   1.021            -0.217   
  TPALpSPQRPLTTQQPQSGTLK            Q64332      Synapsin-2           1.376    0.011   0.438            0.418    
  AWGISVLNPdNK                      P31996      Macrosialin          2.719    0.003   1.881            1.794    
  EAFdNETNQAIQTISR                  P41233      ATP-BC A 1           1.022    0.040   0.720            0.874    
  DdNATQEEILHYLEK                   Q61207      Sulf. Glycoprot.1    1.476    0.014   1.156            1.357    
  EGEEPTVYpSDDEEPK                  O55022      Progesterone R       2.235    0.011   1.144            0.048    
  VAAGHELQPLAIVDQRPSpSR             P23242      Gap junction α-1     1.228    0.041   0.961            0.490    
  DLGPALAdNSSHDVK                   P17439      Ceramidase           1.560    0.049   0.999            0.780    
  pSAEDLTDGSYDDILNAEQLK             Q9D0L7      AR-containing p10    1.147    0.049   1.093            0.881    
  EdNITAEALDLSLK                    Q61704      Trypsin inhib.H3     3.325    0.002   1.380            0.900    
  VVLHPdNHSVVDIGLIK                 Q61646      Haptoglobin          2.244            3.230    0.014   0.405    
  NLFLdNHSETASAK                                                     0.920            3.621    0.012   0.725    
  EEAKpSPGEAKpSPGEAK                P19246      Neurofilament H      2.150            2.889    0.048   -0.311   
  GVVTNGLDVpSPAEEKKGEDSSDDK         P08553      Neurofilament M      -6.053   0.039   -1.546           -3.232   0.030
  TTHYGSLPQKpSQHGR                  P04370      Myelin basic prot.   -4.866           -1.751           -4.179   0.012
  FFpSGDRGAPK                                                        -0.702           -1.974           -3.758   0.014
  NIVTPRpTPPPSQGK                                                    -2.850   0.000   -1.920           -0.938   
  NIVpTPRTPPPSQGK                                                    -2.498   0.000   -1.810           -0.900   
  EAENTANQAGNEpSPVQELRQDVSK         Q6NVE8      WDR-contain. p44     -1.297           -0.542           -2.456   0.014
  SHTSEDARLdNIpTPNSGATGNNAGPK       Q62433      Protein NDRG1        -1.374           -0.832           -2.134   0.014
  DLHESSFpSLSGSQIDDHVPK             Q9EQF6      Dhpyrimidinase 5     0.115            -0.181           -1.617   0.004
  GKPVPIHGpSR                       P16330      cNMP 3\'-PDE         -1.541           -0.158           -1.568   0.013
  HQPAApSPVVVR                      Q9D2P8      Myelin-assoc. OBP    -2.272   0.001   -1.340           -0.945   
  EHANIDAQSGSQAPNPSTpTISPGKSPPPAK   Q8VDQ8      Sirtuin-2            -1.130   0.008   -1.264           -0.653   
  EHANIDAQSGSQAPNPpSTTISPGKSPPPAK                                    -1.406   0.012   -1.346           -0.586   
  QPGFPQPSPSDDPSLpSPRQDR            Q91VC7      Phosphatase 1        -1.673   0.003   -1.635           -1.012   
  pTPSPPEPEPAGTAQK                  Q80YN3      BCAS 1 homolog       -1.072   0.019   -1.225           -0.539   
  AVSpSPTVSR                        Q7TQD2      Tubulin PPP          -2.207   0.027   -1.196           -0.459   
  VVVHKETEIpTPEDGED                 Q9WV92      Band 4.1-like p3     -4.207   0.003   -0.775           -0.200   
  QKFHDpSEGDDTEETEDYR               Q8K019      Bcl-2-assoc. TF1     -2.924   0.041   -0.916           0.167    
  LIDLEpSPTPESQK                    Q8C0T5      SIPA 1-like p1       -0.581           -1.252   0.048   -0.689   

The concentrations of the proteins in the different experimental groups were normalised to those of C group and were expressed in log~2~(fold change) values. Peptide sequences are indicated, phosphorylated peptides are shaded yellow. Blank lines below a protein's access \# and name indicate that the particular protein was identified by more than one PTM peptides. Significant difference from the control is indicated by presenting the q value, and shading red the increases and green the decreases. Those proteins that were identified as both unmodified and single- or multi phosphorylated and/or gycosylated are shaded grey.

As we \[[@pone.0230249.ref015]\] and others \[[@pone.0230249.ref013], [@pone.0230249.ref022]\] demonstrated previously, 4 weeks of cuprizone treatment caused massive demyelination in the corpus callosum that was followed by rapid remyelination when the treatment was discontinued \[[@pone.0230249.ref013], [@pone.0230249.ref022]\]. Accordingly, we expected proteins specific for demyelination-, early- and late remyelination, i.e. proteins with levels that differed from the C group respectively in the 4wD, 2dR and 2wR groups only. Based on this definition, we identified 39 demyelination specific, 24 early- and 48 late remyelination specific unmodified ([Fig 2A](#pone.0230249.g002){ref-type="fig"}), and 18, 3 and 9 PTM proteins ([Fig 2B](#pone.0230249.g002){ref-type="fig"}), respectively. On the other hand, although in different extent, 30 unmodified and 6 PTM proteins were affected in two, while 20 unmodified and 3 PTM proteins in all three groups ([Fig 2](#pone.0230249.g002){ref-type="fig"}).

Immunohistochemical analysis of phosphorylation during de- and remyelination {#sec016}
----------------------------------------------------------------------------

Many cellular functions are regulated by phosphorylation, and the observed uneven distribution of phosphorylation among up- and downregulated PTM proteins raised the possibility of a specific role for phosphorylation during de- and remyelination. Accordingly, we performed immunohistochemistry utilising p-Ser, p-Thr and p-Tyr specific primary antibodies on brain sections of the animals from all four experimental groups. We observed intermediate to weak specific staining that was localised to the nerve fibres rather than the cell bodies or nuclei ([Fig 3A](#pone.0230249.g003){ref-type="fig"}). Seldom, staining of a nucleus or a cell body was found, however, no specific pattern or staining characteristric for a certain cell type could be identified ([Fig 3A](#pone.0230249.g003){ref-type="fig"}). In an attempt to correlate phosphorylation with either de- or remyelination, we measured staining intensities among the brain sections by using an image analyser software. We found up to about 9, 17 and 26% differences among the groups for Ser, Thr and Tyr phosphorylation, respectively ([Fig 3B](#pone.0230249.g003){ref-type="fig"}). Also, the staining intensities were lower in early remyelination than in the control and the demyelination groups for Thr and Tyr phosphorylation, respectively ([Fig 3B](#pone.0230249.g003){ref-type="fig"}).

![Immunohistochemical analysis of phosphorylation during de- and remyelination.\
We performed immunohistochemistry utilising phospho (p)-Ser, p-Thr and p-Tyr specific primary antibodies on brain sections of the animals (n = 3) from all four treatment groups. Representative sections are presented (**A**). For quantitative assessment of phosphorylation during de- and remyelination (**B**), all nuclei and staining artefacts were eliminated from the sections, and staining intensities of corpus callosum were normalised by an expert blind to the experiment to background i.e. left and right retrosplenial area, ventral part, layer 1 (lightly stained area containing few nuclei left and right to the arrow in **A**) by using Molecular Devices' MetaXpress® image analyser software. Data are presented mean ± standard deviation % of the background (n = 3). Filled, dark grey, open and light grey bars denote control, 4-week demyelination, 2-day and 2-week remyelination groups, respectively. \* significantly different from C; \# significantly different from 4W.](pone.0230249.g003){#pone.0230249.g003}

GO analysis of proteins affected by de- and remyelination {#sec017}
---------------------------------------------------------

In order to identify specific biological processes, we performed over-representation test on the proteins affected by de- and remyelination. This test determines representation of the proteins in question in molecular function, biological process or cellular component categories selected as significant ones by the software over estimated representation of the mouse proteome in the same categories. We pooled the differentially regulated 192 PTM and unmodified proteins, and performed the test for biological processes. All the proteins but two were classified into 76 categories, an extract of which is presented in [Table 3](#pone.0230249.t003){ref-type="table"}. The biological process categories included glial and neuronal function, metabolism, cell death, inflammatory response, protein and cation homeostasis, and cytoskeleton related processes ([Table 3](#pone.0230249.t003){ref-type="table"}). Besides the expected oligodendrocyte compatible ones, the overrepresentation test indicated involvement of astrocyte and microglia related events such as glutamate metabolic process \[[@pone.0230249.ref023]\] and inflammatory response \[[@pone.0230249.ref024], [@pone.0230249.ref025]\]. These data are consistent with the accepted view that CPZ induced oligodendrocyte loss is accompanied by expansion and activation of microglia and astrocytes \[[@pone.0230249.ref026]\].

10.1371/journal.pone.0230249.t003

###### Extract of panther biological process over-representation test for the proteins significantly altered in the experimental groups.

![](pone.0230249.t003){#pone.0230249.t003g}

                                                                    \# Mus   Client Text Box Input                   
  ----------------------------------------------------------------- -------- ----------------------- ------- ------- ----------
  myelin maintenance                                                15       3                       0.13    23.47   2.73E-02
  positive regulation of cholesterol transport                      24       4                       0.2     19.56   8.12E-03
  negative regulation of catalytic activity                         671      16                      5.72    2.8     1.80E-02
  neurofilament bundle assembly                                     3        2                       0.03    78.23   3.82E-02
  negative regulation of amyloid fibril formation                   3        2                       0.03    78.23   3.80E-02
  regulation of postsynaptic membrane organization                  21       4                       0.18    22.35   5.78E-03
  response to calcium ion                                           128      7                       1.09    6.42    1.22E-02
  synapse organization                                              258      11                      2.2     5       2.69E-03
  walking behavior                                                  47       4                       0.4     9.99    4.64E-02
  response to toxic substance                                       287      9                       2.45    3.68    4.90E-02
  positive regulation of apoptotic process                          615      14                      5.24    2.67    4.88E-02
  negative regulation of cell death                                 1018     22                      8.68    2.54    7.08E-03
  inflammatory response                                             429      12                      3.66    3.28    2.55E-02
  negative regulation of protein homooligomerization                11       4                       0.09    42.67   1.18E-03
  positive regulation of sodium ion export across plasma membrane   4        3                       0.03    88.01   2.76E-03
  cellular potassium ion homeostasis                                14       3                       0.12    25.15   2.45E-02
  positive regulation of calcium ion transport                      133      7                       1.13    6.18    1.44E-02
  actin filament organization                                       223      12                      1.9     6.31    2.43E-04
  negative regulation of blood coagulation                          45       5                       0.38    13.04   6.58E-03
  response to caloric restriction                                   3        2                       0.03    78.23   3.79E-02
  Unclassified                                                      1873     2                       15.96   0.13    2.48E-03

Protein list from Tables [1](#pone.0230249.t001){ref-type="table"} and [2](#pone.0230249.t002){ref-type="table"} were combined and biological process over-representation test was performed by using Protein Analysis Through Evolutionary Relationships (PANTHER) classification system software ([http://www.pantherdb.org](http://www.pantherdb.org/)). \# Mus musculus and \# denotes the number of proteins in the given category based on the mouse genome and the actual number of proteins in the aforementioned list, respectively. "Expected" indicates the expected number of proteins in the aforementioned list in the case of no over- or under-representation. Fold Enrich. = \#/ expected; the fold over- or under-representation. Significance of the analysis is indicated by presenting the q value.

In addition to the two unclassified proteins, we eliminated those that were involved in biological processes of less than 50% over- or under-representation. We divided the remaining 157 proteins ([Fig 4](#pone.0230249.g004){ref-type="fig"}) into remyelination only (RO, [Fig 4](#pone.0230249.g004){ref-type="fig"} shaded) and demyelination related (DR, [Fig 4](#pone.0230249.g004){ref-type="fig"} unshaded) groups and performed over-representation test on them. The biological process over-representation test allocated the DR proteins into 9 categories ([Table 4](#pone.0230249.t004){ref-type="table"}). For the RO proteins, the single significant category was nervous system development that included myelination as the most specific subcategory ([Table 5](#pone.0230249.t005){ref-type="table"}). Interestingly, a biological process over-representation test on the 60 demyelination specific proteins of the DR group did not identify any significant process.

![Venn diagrams for the shortlisted proteins.\
Those proteins of Tables [1](#pone.0230249.t001){ref-type="table"} and [2](#pone.0230249.t002){ref-type="table"} that were PANTHER unclassified or belonged to a biological process of smaller than 50% over- or under-representation were deleted from the list. Distribution of the 157 remaining unmodified and single- or multi phosphorylated and/or gycosylated proteins among the different experimental groups (see [Fig 1](#pone.0230249.g001){ref-type="fig"}) are presented. Remyelination only proteins are shaded.](pone.0230249.g004){#pone.0230249.g004}

10.1371/journal.pone.0230249.t004

###### Panther biological process over-representation test for the shortlisted demyelination related proteins.

![](pone.0230249.t004){#pone.0230249.t004g}

                                                  \# Mus   Client Text Box Input                  
  ----------------------------------------------- -------- ----------------------- ------- ------ ----------
  regulation of synaptic plasticity               207      8                       0.97    8.29   1.16E-02
      regulation of trans-synaptic signaling      506      11                      2.36    4.66   2.99E-02
      regulation of biological process            11120    72                      51.87   1.39   4.65E-02
      biological regulation                       11734    77                      54.73   1.41   1.59E-02
      regulation of biological quality            3830     43                      17.87   2.41   1.45E-04
  actin filament organization                     223      8                       1.04    7.69   1.62E-02
      supramolecular fiber organization           444      14                      2.07    6.76   2.13E-04
      actin cytoskeleton organization             462      12                      2.16    5.57   4.65E-03
      cytoskeleton organization                   1004     20                      4.68    4.27   2.28E-04
      actin filament-based process                520      13                      2.43    5.36   3.00E-03
  cellular metal ion homeostasis                  551      11                      2.57    4.28   3.97E-02
      metal ion homeostasis                       629      12                      2.93    4.09   3.18E-02
      cation homeostasis                          696      13                      3.25    4      2.77E-02
      ion homeostasis                             777      13                      3.62    3.59   4.52E-02
      homeostatic process                         1588     20                      7.41    2.7    3.13E-02
      inorganic ion homeostasis                   711      13                      3.32    3.92   3.02E-02
      cellular cation homeostasis                 610      12                      2.85    4.22   2.93E-02
      cellular ion homeostasis                    624      12                      2.91    4.12   3.09E-02
      cellular homeostasis                        828      14                      3.86    3.62   3.02E-02
  regulation of cellular component biogenesis     908      16                      4.24    3.78   1.06E-02
  regulation of cell migration                    870      14                      4.06    3.45   4.00E-02
      regulation of localization                  2764     33                      12.89   2.56   6.69E-04
  regulation of transport                         1897     24                      8.85    2.71   1.03E-02
  regulation of cellular component organization   2479     31                      11.56   2.68   8.18E-04
  system development                              4126     37                      19.25   1.92   3.13E-02
  positive regulation of biological process       5897     48                      27.51   1.75   2.09E-02

Those proteins of Tables [1](#pone.0230249.t001){ref-type="table"} and [2](#pone.0230249.t002){ref-type="table"} that were PANTHER unclassified or belonged to a biological process of smaller than 50% over- or under-representation were deleted from the list. Demyelination related proteins were classified as those 107 unmodified and single- or multi phosphorylated and/or gycosylated proteins that were significantly different from the control in the cuprizone treated group ([Fig 4](#pone.0230249.g004){ref-type="fig"}, unshaded). For the explanation, see [Table 3](#pone.0230249.t003){ref-type="table"}.

10.1371/journal.pone.0230249.t005

###### Panther biological process over-representation test for the shortlisted remyelination only proteins.

![](pone.0230249.t005){#pone.0230249.t005g}

                                   \# Mus   Client Text Box Input                  
  -------------------------------- -------- ----------------------- ------ ------- ----------
  myelination                      103      6                       0.23   25.98   2.45E-03
      axon ensheathment            105      6                       0.24   25.48   9.08E-04
      ensheathment of neurons      105      6                       0.24   25.48   1.36E-03
      nervous system development   2178     18                      4.88   3.69    2.20E-03

Those proteins of Tables [1](#pone.0230249.t001){ref-type="table"} and [2](#pone.0230249.t002){ref-type="table"} that were PANTHER unclassified or belonged to a biological process of smaller than 50% over- or under-representation were omitted. Remyelination only proteins were classified as those 50 unmodified and single- or multi phosphorylated and/or gycosylated proteins that were significantly different from the control in the early and late remyelination groups only ([Fig 4](#pone.0230249.g004){ref-type="fig"}, shaded). For the explanation, see [Table 3](#pone.0230249.t003){ref-type="table"}.

To further study the RO proteins ([Fig 4](#pone.0230249.g004){ref-type="fig"}, shaded) for their involvement in mechanisms regulating remyelination, we used Ingenuity Pathway Knowledge Base to select a group of interconnected nodes to assess their cellular level changes during the phases of 2dR and 2wR. The analyses performed on the two remyelination groups resulted the same sole network of eight members ([Fig 5A](#pone.0230249.g005){ref-type="fig"}). In early remyelination, two of them were upregulated and the other six members not affected significantly, while the reverse pattern was observed during late remyelination ([Fig 5A](#pone.0230249.g005){ref-type="fig"}). We searched occurrence of the eight genes among genes expressed differentially between human multiple sclerosis lesion types vs. NAWM \[[@pone.0230249.ref020]\]. As we found, four of them were differentially expressed in at least one of the lesion types, and perlecan (*HSPG2*) gene was the most upregulated in remyelinating lesions ([Fig 5B](#pone.0230249.g005){ref-type="fig"}). In remyelinating multiple sclerosis lesions, the gene expression pattern of the identified experimental remyelination network orthologues was more consistent with early remyelination in the CPZ model, i.e. upregulation of *HSPG2* and downregulation of signal transducer and activator of transcription 1 (*STAT1*) and Thrombospondin-4 (*THBS4*) ([Fig 5B](#pone.0230249.g005){ref-type="fig"}).

![IPA regulator network analysis of RO proteins.\
IPA regulator network analysis was performed on the 2dR and 2wR groups of RO proteins. The resulting network is presented (**A**). Occurrence of the network orthologues among genes expressed differentially between human multiple sclerosis lesion types vs. NAWM \[[@pone.0230249.ref020]\] was studied by using the edgeR package (3.8) software \[[@pone.0230249.ref019]\]. The results are presented as a heat map. Key for molecule shapes and colors as well as relationship labels is published on <http://qiagen.force.com/KnowledgeBase/articles/Basic_Technical_Q_A/Legend>. Significant changes represented by node coloring based on the fold changes in protein levels.](pone.0230249.g005){#pone.0230249.g005}

Discussion {#sec018}
==========

Due to the lack of clear concept for the aetiology of multiple sclerosis, clinical treatment strategies are limited to delaying progression of the disease by suppressing inflammation \[[@pone.0230249.ref027]\]. Recently, proteomic analysis of CPZ treated mice's brain samples was suggested as a potentially useful approach for finding therapeutic targets enabling causal treatment of the disease \[[@pone.0230249.ref028]\]. However, none of the previous studies \[[@pone.0230249.ref010]--[@pone.0230249.ref012]\] targeted the corpus callosum, where CPZ-induces the most pronounced demyelination \[[@pone.0230249.ref013]\]. Therefore, we assessed proteomic changes during de- and remyelination at different time points in the isolated corpus callosum of CPZ treated mice.

Although all previous proteomic studies used mice of the C57BL/6 genetic background, there were differences between genders of the animals, age of the mice at the start and length of CPZ treatment, and the timing of sample acquisition during de- and remyelination \[[@pone.0230249.ref010]--[@pone.0230249.ref012]\]. As we demonstrated previously \[[@pone.0230249.ref015]\], CPZ induced demyelination increases in extent rapidly during the first 4 weeks, then at a much slower rate for the following 2 weeks before the time window for regeneration closes \[[@pone.0230249.ref013]\]. Accordingly, we followed the same protocol as previously \[[@pone.0230249.ref014], [@pone.0230249.ref021]\], namely, 4 weeks of CPZ treatment (demyelination) followed by 2 (early remyelination) and 14 (late remyelination) days of recovery after termination of the CPZ treatment. Proteomic analysis of the corpus callosums resulted in altogether 4886 proteins, however, initial clustering of them did not indicate any group whose concentration changes followed a pattern indicative of de- and remyelination regulators ([Fig 1](#pone.0230249.g001){ref-type="fig"}).

We could select altogether 192 proteins whose concentration was significantly different from the control in at least one experimental group (Tables [1](#pone.0230249.t001){ref-type="table"} and [2](#pone.0230249.t002){ref-type="table"}). They represented a high variety of molecular functions, few of which were characteristic of de- and remyelination processes. Out of the altogether 57 demyelination specific proteins, 25 had more than 1.5 fold of increased and 14 of decreased concentration (Tables [1](#pone.0230249.t001){ref-type="table"} and [2](#pone.0230249.t002){ref-type="table"}). Among the latter, myelin basic protein (MBP) decreased to 13.9 while myelin-associated oligodendrocyte basic protein to 20.8% of their respective level in the control group ([Table 2](#pone.0230249.t002){ref-type="table"}) clearly in accord with the massive demyelination and oligodendrocyte loss occurring in the 4wD group \[[@pone.0230249.ref014]\]. We identified myelin basic protein based on three of its phosphopeptides; one of them bearing two threonine phosphorylation sites ([Table 2](#pone.0230249.t002){ref-type="table"}). Phosphorylation of these sites by mitogen activated protein kinases (MAPKs) was reported to dramatically reduce the protein's binding to negatively charged lipid bilayers \[[@pone.0230249.ref029]\]. Considering that MAPKs are activated during the treatment \[[@pone.0230249.ref015]\], these phosphorylation changes are consistent with the cuprizone induced demyelination. Additionally, besides 17 proteins involved in lipid metabolism, we found two more myelin-associated proteins; 2\',3\'-cyclic-nucleotide 3\'-phosphodiesterase \[[@pone.0230249.ref030]\] and ermin \[[@pone.0230249.ref031]\]. Interestingly, the latter occurred at decreased concentrations in all three experimental conditions ([Table 1](#pone.0230249.t001){ref-type="table"}) that is hard to harmonize with its role in cytoskeletal rearrangements during myelinogenesis and maintenance of myelin sheath's stability \[[@pone.0230249.ref031]\]. In line with the expectations, majority of the 27 early and 54 late remyelination specific proteins (Tables [1](#pone.0230249.t001){ref-type="table"} and [2](#pone.0230249.t002){ref-type="table"}) were associated with myelin sheath, neuronal processes, synapse and cytoskeleton organisation ([Table 5](#pone.0230249.t005){ref-type="table"}). However, out of the major oligodendrocyte marker proteins we found PTM form of myelin-associated oligodendrocyte basic protein and MBP only. On the other hand, we found decreased phosphorylated MBP levels ([Table 2](#pone.0230249.t002){ref-type="table"}) as others did previously in multiple sclerosis patients' and cuprizone mice's brains \[[@pone.0230249.ref032]\]. Furthermore, our finding that all but one decreased PTM proteins were phosphorylated is in line with the view that decreased phosphorylation could be part of demyelination pathogenesis \[[@pone.0230249.ref032]\]. Unfortunately, the immunohistochemical study we performed to assess protein phosphorylation during de- and remyelination proved to be inconclusive. Although we found that Ser, Thr and Tyr phosphorylation was localised to the white matter, it seemed to be associated with the nerve fibres, did not change considerably among the groups, and no clear pattern or cell type specific staining could be identified ([Fig 3](#pone.0230249.g003){ref-type="fig"}).

In contrast to the remyelination only proteins, demyelination-related proteins were not associated ([Table 4](#pone.0230249.t004){ref-type="table"}) with their respective expected biological process categories such as oligodendrocyte apoptosis, demyelination, oxidative stress or mitochondrial damage. Instead, a number of DR proteins were categorized into biological processes related to cytoskeletal and organelle reorganization, metal ion homeostasis and migration; processes most probably associated with astrocytosis and microglia activation \[[@pone.0230249.ref026]\]. Furthermore, the 60 demyelination only DR proteins could not be classified into any biological process category indicating that classification of these proteins with acceptable statistical significance was possible only when they were combined with the proteins that had altered level in two or all three experimental groups.

IPA network construction performed on early and late RO proteins resulted in a sole network, the members of which were activated in an inverse pattern during early vs. late remyelination ([Fig 5A](#pone.0230249.g005){ref-type="fig"}). Four out of the eight members were differentially expressed between human multiple sclerosis lesion types vs. NAWM ([Fig 5B](#pone.0230249.g005){ref-type="fig"}). Clusterin (*CLU*) that we found to be upregulated in all lesion types functions as an extracellular chaperone. It prevents aggregation of non-native proteins and maintains them in a state appropriate for refolding by ATPase chaperones \[[@pone.0230249.ref033]\]. In agreement with our results, *CLU* mRNA levels were reported to be elevated in glial fibrillary acidic protein-positive astrocytes in white matter lesions over NAWM, but not in grey matter of multiple sclerosis patients \[[@pone.0230249.ref034]\]. *HSPG2* that we found to be upregulated in inactive and remyelinating multiple sclerosis lesions is one of the largest extracellular matrix molecules. It was not so far associated with multiple sclerosis, however was suggested to be essential in establishing and patrolling tissue borders \[[@pone.0230249.ref035]\]. *STAT1* acts as a transcription factor for various growth factors. In agreement with other studies \[[@pone.0230249.ref036]\], we found it to be downregulated in inactive and remyelinating lesions. *THBS4* that we found to be downregulated in inactive multiple sclerosis lesions is an adhesive glycoprotein involved in cell-to-cell and cell-to-matrix interactions. Although not in association with multiple sclerosis, it was reported to play a role in tissue remodeling \[[@pone.0230249.ref037]\]. Taken together all information, a role for this predicted network in regulating remyelination processes does not seem compelling, therefore more studies are needed to identify mechanisms regulating de- and remyelination.

Conclusions {#sec019}
===========

Taken together all aforementioned data, proteomic analysis of the cuprizone treated corpus callosum seems more informative for the processes of remyelination over those of demyelination. In a broader sense, these results may indicate limitations of the cuprizone model in answering demyelination related specific questions in multiple sclerosis research by proteomics.
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